Trial Profile
A Randomised, Double-Blind, Parallel-Group, Flexible-Dose Study Exploring the Neurocognitive Effect of Sertindole Versus Comparator in Patients With Schizophrenia Using the MATRICS Consensus Cognitive Battery (MCCB).
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 09 Nov 2021
Price :
$35
*
At a glance
- Drugs Sertindole (Primary) ; Quetiapine
- Indications Schizophrenia
- Focus Therapeutic Use
- Sponsors Lundbeck A/S
- 05 May 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 27 Jan 2010 Actual patient number (264) added as reported by ClinicalTrials.gov.
- 27 Jan 2010 Planned end date changed from 1 Feb 2010 to 1 Mar 2010 as reported by ClinicalTrials.gov.